CD274 and neoplasm: Recent studies have shown that activating KRAS mutations may induce an immunosuppressive tumor microenvironment (TME) by modulating major histocompatibility complex class I (MHC-I) via autophagocytosis 3, 4, as well as by regulating the level of PD-L1 5.